BASKING RIDGE, N.J., Feb. 1 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VQPH), a New Jersey-based biopharmaceutical company, announced today the appointment of Edward C. Bradley, M.D. as Chief Scientific Officer.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070201/NYTH141

             http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

Dr. Bradley joins VioQuest from Berlex Laboratories, a wholly-owned US subsidiary of Schering AG, (now Bayer-Schering Pharma) where he held the position of Chief Medical Officer and reported to the President of Berlex Laboratories. As such, he had direct responsibility for all aspects of clinical drug development and medical affairs from Phase I through Phase IV, professional services, corporate product safety, biometrics, medical communications, and medical governance.

Dr. Bradley said, "I am delighted to join VioQuest at this particular point in its corporate life. With four clinical trials underway for its two drug candidates and Orphan Drug designation and a pending NDA for one of them, it's an opportune time to join the team. I look forward to the further clinical advancement of these drugs which are at the forefront of targeted oncologic therapeutics."

He continued, "VioQuest's strategy of focusing on molecules with a known clinical safety profile and an early demonstration of therapeutic activity should facilitate rapid clinical development cycle times. The choice of molecules which allow patient-specific therapy could provide a straightforward approval path and, following approval, logical integration into the real-world practice of oncology. The promising science and growing clinical data for VQD-001 and VQD-002 are significant not only for their own sake but because they support the feasibility of this strategy. New science, new pharmacoeconomic expectations and a new global regulatory environment are already showing the need for a change in the current paradigm, and it's exciting to join a company which is on the leading edge of that change."

Daniel Greenleaf, President and CEO of VioQuest Pharmaceuticals, said, "We are all delighted with Ed's decision to join us. He brings a record of successful new drug development, leadership and value creation within the pharmaceutical industry. He is a recognized contributor to organizational growth and has a significant leadership track record. He has an excellent reputation for solid grounding in science and commitment to patients."

Mr. Greenleaf continued, "The addition of Ed Bradley to our team comes at a most opportune time. This year, we expect to provide clinical trial updates for VQD-001 and VQD-002, complete enrollment in all corporate sponsored Phase I trials, initiate Phase IIa trials for VQD-001 and VQD-002, and commence certain Phase IIb trials."

Prior to his employment with Berlex Laboratories, Dr. Bradley was Executive Vice President, Worldwide Medical Science & Development at DuPont Pharmaceuticals from 1997 until its acquisition by Bristol-Myers in 2002. Prior to DuPont Pharmaceuticals, Dr. Bradley's employment was Senior Vice President, Clinical Development, Sanofi Recherche (corporate) and Chief Medical Officer, Sanofi, Inc. (USA); Senior Vice President, Portfolio Management, Sanofi-Winthrop Research Division; Senior Vice President, Oncology in the Pharmaceutical Research Division of Sterling-Winthrop; and Executive Vice President with the Immunoconjugates Division.

Dr. Bradley is a Diplomat of the American Board of Internal Medicine and is certified by the Board of Medical Oncology. He received his MD degree from Harvard Medical School, where he also did his internship, residency, and a Chief medical residency. He served as a clinical associate at the National Cancer Institute, National Institutes of Health, has held clinical appointments at Harvard and Stanford University, served on the editorial board of scientific journals, and has been published in numerous peer reviewed medical journals in the areas of oncology and tumor immunology.

About VioQuest Pharmaceuticals

VioQuest Pharmaceuticals, Inc. www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which inhibits phosphorylation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and VQD-001, an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for VQD-001 for the treatment of leishmaniasis. VioQuest's subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. VioQuest is seeking strategic alternatives for Chiral Quest, which may include its sale.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Further, there us no assurance that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that its planned and ongoing clinical trials will not be initiated or completed as anticipated, that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    Contact information:

    Daniel Greenleaf
    President and CEO
     ext. 115
    

    Ed Bradley
    Chief Scientific Officer
     ext. 118
    

    Brian Lenz
    Chief Financial Officer
     ext. 117
    

    Diane Perry
    VP, Investor Relations & Corporate Communications
     or  ext. 116
    

SOURCE VioQuest Pharmaceuticals, Inc.